Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,413 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Parkinson's Disease Clear all

Conditions: Parkinson Disease
Interventions: Neurophysiology recordings, Neural stimulation; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson's Disease
Interventions: IPX066; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • Sunnyvale, California + 5 more

Conditions: PD - Parkinson's Disease
Interventions: Medtronic Percept Deep Brain Stimulation (cDBS), Medtronic Percept Deep Brain Stimulation (daytime aDBS), Medtronic Percept Deep Brain Stimulation (nighttime aDBS); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
Interventions: Stereotactic brain procedures; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 90 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions: Pimavanserin, Quetiapine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: BlueRock Therapeutics; Industry
Eligibility: 50 Years to 78 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Orange, California • New York, New York

Conditions: Parkinson Disease
Interventions: Auditory Cueing, Visual Cueing, tactile Cueing; Other
Lead sponsor: Northumbria University; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 103
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 100 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions: Retinal and Choroidal Imaging; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease
Interventions: Deep Brain Stimulation (DBS); Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: Placebo, Tozadenant; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson's Disease and Parkinsonism, Glymphatic System
Interventions: Exercise--Rock Steady Boxing class; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson's Disease
Interventions: Donepezil; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Parkinson Disease
Interventions: ursodeoxycholic acid; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Parkinson Disease, Covid19, Satisfaction, Patient, Quality of Life
Interventions: No Intervention; Other
Lead sponsor: Towson University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Parkinson Disease
Interventions: Group A - Early Imaging, Group B - Delayed Imaging; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease, Dementia, Lewy Body, Delirium
Interventions: Music therapy intervention, Standard Care (in control arm); Behavioral · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Parkinson Disease
Interventions: Video and Activity Tracker; Other
Lead sponsor: Jacob E. Simmering; Other
Eligibility: 50 Years to 110 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Parkinson Disease
Interventions: CVL-751; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Atlanta, Georgia

Conditions: Parkinson's Disease and Parkinsonism
Interventions: Lab Assay for seven genetic variants for Parkinson's Disease; Device
Lead sponsor: Parkinson's Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Fort Lauderdale, Florida + 9 more

Conditions: Parkinson's Disease
Interventions: Peripheral Nerve Tissue Implantation; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Sun City, Arizona • Irvine, California + 34 more

Search by objective public record fields.

Neurophysiology of Reward Signaling in Parkinson's Disease

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease

Physiological Brain Atlas Development

Comparing Antipsychotic Medications in LBD Over Time

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

Brain Activity During Gait in Parkinson's

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

Retinal Imaging in Neurodegenerative Disease

Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease

Study to Evaluate SYN115 in Parkinson's Disease

Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

PET Imaging in Parkinson Disease Dementia

Effects of Cholinergic Augmentation on Measures of Balance and Gait

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic

Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects

Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies

Remote Monitoring in Parkinson's Disease

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

PDGeneration: Mapping the Future of Parkinson's Disease

Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease